Novartis Dismisses Some Exelon Patent Claims

Law360, New York (April 23, 2007, 12:00 AM EDT) -- A federal judge on Thursday approved Novartis Pharmaceuticals Corp.’s requests to dismiss claims for infringement of one patent involved in a multidistrict dispute over Exelon, the Swiss drug maker’s Alzheimer’s treatment.

U.S. Magistrate Judge James C. Francis IV of the U.S. District Court for the Southern District of New York approved Novartis’ motion to dismiss claims it had brought against Watson Pharmaceuticals Inc. and Sun Pharmaceutical Industries Ltd. for infringement of U.S. Patent Number 5,602,176, but only after some additional conditions are added to Novartis’ agreements...
To view the full article, register now.